Position in BBIO
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$10,340,430
+$6,086,446 QoQ
Shares Held
138,835
+142.4% QoQ
Ownership
0.071%
of shares outstanding
% of Portfolio
2.20%
of 13F equity value
Holder Rank
#117
of 467 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARVEY CAPITAL MANAGEMENT INC holds $41,212,465 across 6 Biotechnology names. BBIO ranks #2 (25.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
146,113 | $11,436,264 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
This page
|
138,835 | $10,340,430 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
26,913 | $6,485,225 | |
| 4 | CYTK |
Cytokinetics Inc
|
68,275 | $5,816,347 | |
| 5 | ARGX |
Argenx SE
|
4,346 | $4,032,088 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,975 | $3,102,111 |
All Filings in BBIO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,340,430 | 138,835 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $4,253,984 | 57,285 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $3,268,417 | 42,730 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $2,224,590 | 42,830 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $2,223,122 | 51,485 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $587,690 | 17,000 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $353,976 | 12,900 | Shares | Sole | 2025-01-29 | |
| No filing history on record for this holder in this stock. | ||||||